explore -WSS

explore

author：knowledge 2025-10-02 22:26:43 - browse：4

Adobe

At least 224 diabetes patients have been harmed by a software error causing their insulin pumps to spontaneously shut down, the Food and Drug Administration announced in a recall notice on Wednesday.

The product is made by Tandem Diabetes Care, which sells touchscreen insulin pumps and an accompanying app to help dose the medicine. Around 300,000 people use the technology. Tandem found that a bug in the app’s software is causing the app to repeatedly crash and relaunch, draining the insulin pump’s battery through unnecessary Bluetooth communication.

An insulin pump shutting down unexpectedly could kill people, especially if the shutdown occurs while the person is sleeping. There have been no reports of death so far, the FDA said. Tandem users commiserated over the issue on Reddit two months ago, with one user describing waking up at 2 a.m. to a dead pump. “Infuriating,” the user wrote. “Absolutely should be sending a notice out to all customers about this.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Was Amgen transparent enough on FDA's concern on cancer drug?

focus

WSS

Key Senate panel to consider PBM, drug pricing reform package

Medicare proceeds with plan to claw back hospital funds

DeepMind touts AlphaFold's new skills as protein folding AI models face off

FDA authorizes Novavax’s updated Covid

FDA panel signals lack of confidence in Amgen cancer drug data

The health care issue Democrats can’t solve: hospital reform

entertainment

explore

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

hotspot

As demand for Covid shots wanes, Moderna seeks its next success

Life sciences investors close nearly $6 billion in new funds

Psychedelics group wrestles with new pharma identity

Readout LOUD podcast: The Sarepta saga, decoding biotech hype

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

A virus, fished out of a lake, may have saved a man’s life

Wildfire smoke exposes gaps in outdoor worker protections

Kidney transplant patients stopped immunosuppressants in trial

Tori Bowie and the unacceptable rates of Black maternal death

Stroke deaths set to near 10 million globally by 2050

hotspot

Bill would stop addiction treatment from triggering child abuse inquiry

A Q&A with the global head of Boehringer Ingelheim's innovation unit

Histogen: Failed biotech offers rare public look inside

Chemotherapy drug shortage eases slightly but still widespread

A Q&A with the global head of Boehringer Ingelheim's innovation unit

FDA rejects Alnylam's heart disease treatment over insufficient data

focus

focus

hotspot

focus